| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 367.29% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 10/16/2023 | 367.29% | Piper Sandler | $30 → $25 | Maintains | Overweight |
| 09/25/2023 | 217.76% | Stifel | $16 → $17 | Maintains | Buy |
| 08/17/2023 | 367.29% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 06/09/2023 | 199.07% | Stifel | $11 → $16 | Upgrades | Hold → Buy |
| 06/09/2023 | 385.98% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 04/27/2023 | 367.29% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 03/17/2023 | 367.29% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/27/2023 | 161.68% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 02/03/2023 | 180.37% | Morgan Stanley | $28 → $15 | Downgrades | Overweight → Equal-Weight |
| 11/17/2022 | 367.29% | HC Wainwright & Co. | $38 → $25 | Maintains | Buy |
| 08/08/2022 | 423.36% | Morgan Stanley | $30 → $28 | Maintains | Overweight |
| 06/06/2022 | 610.28% | HC Wainwright & Co. | $54 → $38 | Maintains | Buy |
| 06/02/2022 | 460.75% | Piper Sandler | $25 → $30 | Maintains | Overweight |
| 04/12/2022 | 105.61% | Stifel | $45 → $11 | Downgrades | Buy → Hold |
| 09/23/2021 | 797.2% | Stifel | → $48 | Initiates Coverage On | → Buy |
| 09/13/2021 | 909.35% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
| 08/16/2021 | 778.5% | Morgan Stanley | $45 → $47 | Maintains | Overweight |
| 06/28/2021 | 759.81% | Guggenheim | → $46 | Initiates Coverage On | → Buy |
| 04/19/2021 | 741.12% | Morgan Stanley | $41 → $45 | Maintains | Overweight |
| 03/01/2021 | 853.27% | Berenberg | → $51 | Initiates Coverage On | → Buy |
| 12/16/2020 | 666.36% | Morgan Stanley | $37 → $41 | Maintains | Overweight |
| 10/28/2020 | — | Northland Capital Markets | Initiates Coverage On | → Outperform | |
| 07/14/2020 | 591.59% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 07/14/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/14/2020 | 647.66% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
What is the target price for Repare Therapeutics (RPTX)?
The latest price target for Repare Therapeutics (NASDAQ: RPTX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $25.00 expecting RPTX to rise to within 12 months (a possible 367.29% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Repare Therapeutics (RPTX)?
The latest analyst rating for Repare Therapeutics (NASDAQ: RPTX) was provided by HC Wainwright & Co., and Repare Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Repare Therapeutics (RPTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Repare Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Repare Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Repare Therapeutics (RPTX) correct?
While ratings are subjective and will change, the latest Repare Therapeutics (RPTX) rating was a reiterated with a price target of $0.00 to $25.00. The current price Repare Therapeutics (RPTX) is trading at is $5.35, which is within the analyst's predicted range.